U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H29F5N3O5.Na
Molecular Weight 653.5728
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELAGOLIX SODIUM

SMILES

Cc1c(-c2cccc(c2F)OC)c(=O)n(C[C@@]([H])(c3ccccc3)NCCCC(=O)[O-])c(=O)n1Cc4c(cccc4F)C(F)(F)F.[Na+]

InChI

InChIKey=DQYGXRQUFSRDCH-UQIIZPHYSA-M
InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C32H29F5N3O5
Molecular Weight 630.583
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Elagolix (ABT-620) is an oral gonadotropin-releasing hormone antagonist being studied for the treatment of endometriosis and uterine fibroids. The U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.

CNS Activity

Curator's Comment:: Elagolix did not cross the blood brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Orilissa

Approved Use

ORILISSA is a gonadotropin -releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis .

Launch Date

1.53230403E12
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1314 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ELAGOLIX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3231 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ELAGOLIX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.48 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ELAGOLIX plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 18 –39 years
n = 5
Health Status: healthy
Age Group: 18 –39 years
Population Size: 5
Sources:
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (0.8%)
Vomiting (0.6%)
Headache (0.8%)
Depression (0.4%)
Hot flush (0.8%)
Insomnia (0.4%)
Irritability (0.4%)
Mood swings (0.4%)
Abdominal pain (0.2%)
Acne (0.2%)
Endometriosis (0.4%)
Migraine (0.2%)
Sources: Page: p. 143
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (1.5%)
Vomiting (0.4%)
Headache (1%)
Depression (0.6%)
Hot flush (2.5%)
Insomnia (0.4%)
Irritability (0.4%)
Mood swings (0.2%)
Abdominal pain (0.4%)
Acne (0.4%)
Facial swelling (0.4%)
Migraine (0.4%)
Depressed mood (0.4%)
Diarrhea (0.6%)
ALT increased (0.4%)
AST increased (0.4%)
Arthralgia (0.6%)
Rash (0.4%)
Sources: Page: p. 143
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 0.2%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Acne 0.2%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Migraine 0.2%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Depression 0.4%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Endometriosis 0.4%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Insomnia 0.4%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Irritability 0.4%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Mood swings 0.4%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Vomiting 0.6%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Headache 0.8%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Hot flush 0.8%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Nausea 0.8%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 475
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 475
Sources: Page: p. 143
Mood swings 0.2%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
ALT increased 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
AST increased 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Abdominal pain 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Acne 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Depressed mood 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Facial swelling 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Insomnia 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Irritability 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Migraine 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Rash 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Vomiting 0.4%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Arthralgia 0.6%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Depression 0.6%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Diarrhea 0.6%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Headache 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Nausea 1.5%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
Hot flush 2.5%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 143
unhealthy, adult (premenopausal women)
n = 477
Health Status: unhealthy
Condition: endometriosis
Age Group: adult (premenopausal women)
Sex: F
Population Size: 477
Sources: Page: p. 143
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 145 uM]
no [IC50 150 uM]
no [IC50 161 uM]
no [IC50 280 uM]
no [IC50 45 uM]
no [IC50 >100 uM]
no [IC50 >300 uM]
weak [IC50 >29 uM]
weak [IC50 >29 uM]
weak [IC50 >30 uM]
weak [IC50 >30 uM]
weak [IC50 >30 uM]
weak [IC50 >30 uM]
yes [IC50 1.7 uM]
yes (co-administration study)
Comment: BCRP/OATP1B1 inhibition by elagolix 300 mg BID ↓AUC by 40% ↔ Cmax (rosuvastatin)
Page: 41.0
yes [IC50 19 uM]
yes [IC50 36 uM]
yes [IC50 4.7 uM]
yes [IC50 54 uM]
yes [Ki 34 uM]
yes [Ki 74 uM]
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: CYP3A4 induction by elagolix 150 mg QD and 300 mg BID ↓AUC by 35 - 55% ↓Cmax by 19 – 44% (midazolam)
Page: 41.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
yes
yes
yes
yes
likely (co-administration study)
Comment: CYP3A4/P-gp induction by rifampin, 600 mg QD ↑Cmax by 100% ↑AUC by 65%
Page: 41.0
yes
yes (co-administration study)
Comment: CYP3A4 inhibition by ketoconazole, 400 mg QD ↑Cmax by 77% ↑AUC by 120%
Page: 41.0
yes
yes (co-administration study)
Comment: OATP1B1 inhibition by a single dose of rifampin, 600 mg ↑Cmax by 337% ↑AUC by 458%
Page: 41.0
Tox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Normal liver function or mild hepatic impairment : 150 mg once daily for up to 24 months or 200 mg twice daily for up to 6 months. (2.1) Moderate hepatic impairment: 150 mg once daily for up to 6 months. (2.1) Oral tablets: 150 mg and 200 mg
Route of Administration: Oral
Elagolix displays high affinity in a competition binding assay for hGnRH-R (Ki = 0.90 nM) and low CYP3A4 inhibition (IC50 = 56 uM). It is a slowly disassociating antagonist exhibiting very high affinity (KD = 54 pM) and insurmountable antagonism. Elagolix is highly selective at hGnRH-R, its wider receptor selectivity is tested at a concentration of 10 uM in a panel of radioligand binding assays for 100 off-target receptors, ion channels, enzymes, and transporters, and significant activity is not observed (inhibition <50%). It does not stimulate histamine release from cultured rat peritoneal mast cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:02:29 UTC 2021
Edited
by admin
on Sat Jun 26 14:02:29 UTC 2021
Record UNII
5948VUI423
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELAGOLIX SODIUM
USAN   WHO-DD  
USAN  
Official Name English
ORIAHNN COMPONENT ELAGOLIX SODIUM
Brand Name English
BUTANOIC ACID, 4-(((1R)-2-(5-(2-FLUORO-3-METHOXYPHENYL)-3-((2-FLUORO-6-(TRIFLUOROMETHYL)PHENYL)METHYL)-3,6-DIHYDRO-4-METHYL-2,6-DIOXO-1(2H)-PYRIMIDINYL)-1- PHENYLETHYL)AMINO)-, MONOSODIUM SALT
Common Name English
ELAGOLIX SODIUM COMPONENT OF ORIAHNN
Brand Name English
ELAGOLIX SODIUM [ORANGE BOOK]
Common Name English
SODIUM 4-(((1R)-2-(5-(2-FLUORO-3-METHOXYPHENYL)-3-((2-FLUORO-6- (TRIFLUOROMETHYL)PHENYL)METHYL)-4-METHYL-2,6-DIOXO-3,6-DIHYDROPYRIMIDIN-1(2H)-YL)-1- PHENYLETHYL)AMINO)BUTANOATE
Systematic Name English
ORLISSA
Brand Name English
ELAGOLIX SODIUM [WHO-DD]
Common Name English
ELAGOLIX SODIUM SALT [MI]
Common Name English
NBI-56418-NA
Code English
ELAGOLIX SODIUM [USAN]
Common Name English
NBI-56418 NA
Code English
Code System Code Type Description
PUBCHEM
24785956
Created by admin on Sat Jun 26 14:02:29 UTC 2021 , Edited by admin on Sat Jun 26 14:02:29 UTC 2021
PRIMARY
CAS
832720-36-2
Created by admin on Sat Jun 26 14:02:29 UTC 2021 , Edited by admin on Sat Jun 26 14:02:29 UTC 2021
PRIMARY
FDA UNII
5948VUI423
Created by admin on Sat Jun 26 14:02:29 UTC 2021 , Edited by admin on Sat Jun 26 14:02:29 UTC 2021
PRIMARY
RXCUI
2049847
Created by admin on Sat Jun 26 14:02:29 UTC 2021 , Edited by admin on Sat Jun 26 14:02:29 UTC 2021
PRIMARY
NCI_THESAURUS
C166831
Created by admin on Sat Jun 26 14:02:29 UTC 2021 , Edited by admin on Sat Jun 26 14:02:29 UTC 2021
PRIMARY
DRUG BANK
DBSALT002117
Created by admin on Sat Jun 26 14:02:29 UTC 2021 , Edited by admin on Sat Jun 26 14:02:29 UTC 2021
PRIMARY
MERCK INDEX
M4850
Created by admin on Sat Jun 26 14:02:29 UTC 2021 , Edited by admin on Sat Jun 26 14:02:29 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL1208155
Created by admin on Sat Jun 26 14:02:29 UTC 2021 , Edited by admin on Sat Jun 26 14:02:29 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY